Analysts’ Recent Ratings Changes for AnaptysBio (ANAB)

A number of firms have modified their ratings and price targets on shares of AnaptysBio (NASDAQ: ANAB) recently:

• 3/30/2026 – AnaptysBio had its “buy” rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
• 3/25/2026 – AnaptysBio was upgraded by Truist Financial Corporation to “hold”.
• 3/17/2026 – AnaptysBio had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a “buy” rating on the stock.
• 3/12/2026 – AnaptysBio had its price target raised by Wedbush from $60.00 to $75.00. They now have an “outperform” rating on the stock.
• 3/6/2026 – AnaptysBio had its price target raised by Truist Financial Corporation from $36.00 to $50.00. They now have a “hold” rating on the stock.
• 3/5/2026 – AnaptysBio had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a “buy” rating on the stock.
• 3/4/2026 – AnaptysBio had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an “overweight” rating on the stock.
• 3/4/2026 – AnaptysBio had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a “buy” rating on the stock.

Insider Activity at AnaptysBio

In related news, insider Paul F. Lizzul sold 3,650 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the sale, the insider owned 42,088 shares of the company’s stock, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dennis Mulroy sold 2,515 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $112,445.65. Following the completion of the transaction, the chief financial officer owned 21,852 shares in the company, valued at $977,002.92. This represents a 10.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 110,193 shares of company stock worth $5,333,138. 33.50% of the stock is currently owned by corporate insiders.

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.